Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain

NCT05359133 is registered in ClinicalTrials.gov with Wex Pharmaceuticals Inc. as lead sponsor.

NCT NCT05359133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05359133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain
Lead sponsor
Wex Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Terminated
Start date
April 19, 2022
Completion date
October 14, 2024
Enrollment
35 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced neuropathic pain, chemotherapy-induced peripheral neuropathy